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among community dwelling older adults using most updated beers criteria and for 
the recent years. Using this criteria, we found that prevalence decreased by almost 
1% for the year 2013 in comparison to the previous year.
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FACTORS ASSOCIATED WITH HAVING PRESCRIPTION DRUG FILLS AMONG 
MEMBERS OF QUALIFIED HEALTH PLANS
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Objectives: To determine factors associated with having one or more prescrip-
tion drug fills (PDFs) in members of qualified health plans (QHPs). MethOds: This 
study used a large nationally representative administrative claims database supple-
mented with socioeconomic and community resource data. The sample consisted 
of 1,823,677 members of QHPs who were enrolled for ≥ 10 months in 2014. Logistic 
regression was used to determine factors associated with having PDFs. Results: 
A total of 1,230,981 (67.5%) members had ≥ 1 PDF during the study period. Living in 
a neighborhood with higher education levels (i.e., percent population with at least 
bachelor’s degree) was associated with higher likelihood of having PDFs (OR: 1.04-
1.12; reference: 0-12%). Lower median household income was associated with lower 
likelihood of having PDFs (OR: 0.73-0.90; reference $100,000+). Members from neigh-
borhoods with a higher proportion of non-white race/ethnicities were less likely 
to have PDFs (non-Hispanic black, OR= 0.80; Hispanic, OR= 0.95; Asian, OR= 0.58). 
Compared to Silver plan members, members of Gold plans were more likely to 
have PDFs (OR= 1.07); but members of Platinum, Bronze, and Catastrophic plans 
were less likely to have PDFs (OR: 0.95, 0.65 and 0.83, respectively). Individual plan 
enrollment was associated with higher likelihood of having PDFs (OR= 1.10), while 
on-exchange plan enrollment was associated with lower likelihood (OR= 0.87). Other 
factors associated with lower likelihood of having PDFs were being male (OR= 0.62); 
younger age (OR: 0.55-0.71; reference: 31-65); and living in a non-metropolitan area 
(OR: 0.89-0.95). cOnclusiOns: This study provides evidence that the likelihood of 
having PDFs varies across member and plan characteristics, even after controlling 
for patient severity. Assuring appropriate treatment and adherence to medications 
for chronic conditions is inherent to achieving good health outcomes, thus it is 
important that QHPs identify and understand factors associated with lower likeli-
hood of filling prescriptions in order to develop targeted interventions to achieve 
the most optimal outcomes in their members.
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Objectives: The remit of this review is to appraise considerations of equity in the 
delivery of personalised medicines. The aim of the review was to analyse evidence 
relating to the assessment of the effects of personalised medicines not aimed at 
reducing inequity but where it is important to understand the effects on equity 
in terms of delivery of care. MethOds: The scope was informed by the Campbell 
and Cochrane Equity Methods Group and the Cochrane Public Health Group who 
recommend the PROGRESS-Plus approach to analyse health inequality information. 
PROGRESS-Plus is an acronym for place of residence, race/ethnicity/culture/lan-
guage/occupation/, gender/sex, religion, socioeconomic status and social capital and 
“Plus” captures other characteristics which may indicate a disadvantage, such as age 
and disability. The categories of focus for identification of factors which may lead to 
health inequalities in our analysis include income, occupation, education, gender, 
ethnicity and age. A total of 202 personalised medicines with differing approvals 
between EMA, FDA, PMDA and HCSC were considered and studies grouped according 
to therapeutic area. A hypothesis testing approach using a harvest plot was chosen 
to assess which of three competing hypotheses; positive social gradient, negative 
social gradient and no gradient is best supported by each study for each dimen-
sion of inequality. Results: Findings of health inequalities will be synthesized by 
presenting relative and absolute differences between groups. Using a harvest plot, 
a positive social gradient in effectiveness was defined as a situation in which the 
personalised medicine was more effective in more advantaged groups whereas a 
negative social gradient in effectiveness was defined as a situation in which a per-
sonalised medicine was more effective in disadvantaged groups. cOnclusiOns: 
The review aims to identify evidence of personalised medicines with a negative 
social gradient to inform policies to reduce inequalities in health and also highlight 
gaps in evidence.
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DOES SOCIETY WISH TO PLACE GREATER WEIGHT ON A UNIT OF HEALTH GAIN 
FOR END-OF-LIFE PATIENTS THAN ON THAT FOR OTHER TYPES OF PATIENTS?
Shah K
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Objectives: The debate on whether health gains should be weighted differently for 
different patient groups has focused recently on the relative value of treatments for 
patients with short life expectancy. It is unclear whether society is prepared to fund 
end-of-life treatments that would not meet the reimbursement criteria used for 
other treatments. Our objective is to review the empirical evidence in the published 
literature relevant to the following research question: Do members of the general 
public wish to place greater weight on a unit of health gain for end-of-life patients 
than on that for other types of patients? MethOds: A systematic approach was 
used to identify and select data for the review. We conducted a keyword search of 
the Social Sciences Citation Index (aided by an innovative approach to ‘searching for 
search terms’), with follow-up of references to obtain additional data. Hierarchical 
criteria were applied to select empirical studies reporting stated preferences relating 
to hypothetical health care priority-setting contexts. Results: Seventeen studies 
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Objectives: To describe personal use, knowledge, and attitudes of pharmacy stu-
dents toward herbal and dietary supplements and to compare students’ use to 
general population use. MethOds: Paper questionnaires were administered to first, 
second and third year PharmD students asking students to identify dietary supple-
ments that they had ever used, assessing their knowledge about adverse effects and 
indicated uses and attitudes. Ever use was compared to the 2007 National Health 
Interview survey findings. Logistic regression was performed to identify factors 
associated with dietary supplement use. Results: There were 179 respondents 
(response rate 60%; 37% men; 78% aged 18-25). About half (52%) of students indi-
cated they had ever used at least one herbal supplement; greater than the 25% use 
reported in the general population. The most commonly used supplement was 
fish oil/omega-3 (46%), followed by fiber/psyllium at 18%; use of all other listed 
supplements was less than 15% indicating low use of most dietary supplements 
among pharmacy students although about a third (38%) of students had used one 
or more of the other listed supplements. Students had limited knowledge about 
herbal and dietary supplements. The knowledge test average score was 50%; 
however third-year students scored significantly higher (61% correct) than first-
year students (41% correct; p< 0.001). Students thought knowledge about herbal 
supplements was important, but their education was inadequate. Students gen-
erally rated dietary supplements as ‘not essential for health’. Logistic regression 
found the variables ‘knowledge’ and ‘recommend to family or friends’ (p < 0.04) 
were associated with use. cOnclusiOns: Generally, pharmacy students did not 
use many dietary/herbal supplements; exceptions were fish oil/omega-3 and fiber/
psyllium. Students had limited knowledge of dietary supplements and suggested 
more education was needed. Herbal supplements were not considered essential 
for health. Logistic regression indicated that students with greater knowledge of 
herbal/dietary supplements were more likely to use them.
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Objectives: To characterize the variance in appearance and costs of 16 oral 
solid generic medications in four major chronic disease/drug management 
classes. MethOds: A commercial drug knowledge database was used to identify 
frequently prescribed oral solid medications that have at least 3 manufacturer 
sources (excluding repackagers and relabelers) for calendar year 2014. Four drugs 
from each of the following chronic therapeutic classes were evaluated; 1) antidia-
betics (glyburide 5mg, metformin 500mg, acarbose 50mg, glipizide 10mg); 2) statins 
(simvastatin 40mg, pravastatin 40mg, atorvastatin 40mg, lovastatin 20mg); 3) beta 
blockers (metoprolol 100mg, atenolol 50mg, carvedilol 25mg, labetolol 100mg); and 
4) heart failure drugs (amlodipine 10mg, losartan 50mg, lisinopril 10mg, valsartan 
40mg). These classes were chosen because they are included in CMS MTM qual-
ity measures. The physical appearance (color, shape, scoring, and size), identify-
ing imprint, and price (WAC) for each manufacturer’s identical strength product 
was assessed as to similarity to the other generic versions. Results: Database 
review obtained the following number of manufacturers per class: antidiabetics= 
43; statins= 39; beta blockers= 38; and heart failure agents= 53. Overall, for all 16 
drugs across all 4 disease states, there was an average of 3 different colors, 2 dif-
ferent shapes, 11 manufacturers, and 4 different images. Individually drugs varied 
from no differences to 8 differences, with color and shape equally contributing to 
variation (n= 8 for > 2 colors and > 2 shapes). Differences in dosage scoring and size 
were minor. cOnclusiOns: There are multiple sources of medications for four 
chronic conditions. With substantial appearance variation among several generi-
cally equivalent products, there is strong possibility that a patient may experience 
a future drug product switch that could increase the likelihood of significant non-
adherence, and ultimately result in adverse disease outcomes through discontinua-
tion of prescribed therapy. Pill appearance variation highlights a potential important 
focus for future chronic disease/medication therapy management.
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Objectives: Prescribing potentially inappropriate medications (PIMs) as first-line 
treatment for older adults has been a major safety concern as PIMs use have been 
associated with negative health outcomes. Our primary objective was to determine 
the prevalence of PIMs among U.S. older adults. The secondary objective was to esti-
mate the total and different types of healthcare expenditures associated with PIMs 
use. MethOds: A retrospective cohort study with patients over age 65 was conducted 
using Medical Expenditures Panel Survey (MEPS) data for the years 2012 (N = 112,154) 
and 2013 (N= 110,072). The prevalence for each year was evaluated using the updated 
2015 Beer’s criteria. As MEPS doesn’t have sufficient details on daily drug dosage, 
frequency, and duration of administration, our analysis included only 21 out of the 
38 listed drugs in the diagnosis-independent criteria. All our analyses accounted for 
the complex sampling design. Results: The prevalence of PIMs among US older 
adults was 5.5% for 2012 and 4.6% for 2013. Amongst all the drug classes, PIMs preva-
lence was highest for the class of CNS-active drugs users (1.3% for 2012, 1% for 2013). 
PIMs use was found to be highest among 65-74 followed by 75-84 and 85+ age group. 
The average annual total healthcare expenditure per PIMs user was $12,969 (95% CI: 
11113, 14825) in 2012 and $14,536 (95% CI: 12254, 16818) in 2013. Amongst types of 
expenditures, prescription, inpatient, and outpatient visits accounted for almost 80% 
of the total expenditures, while emergency and other expenditures were less than 
20% for both years. cOnclusiOns: This study found the prevalence for PIMs users 
